Abstract: Angiogenesis, the process of new blood vessel formation, is implicated in various physiological/pathological conditions, including embryonic development, inflammation and tumor growth. Fibroblast growth factor-2 (FGF2) is a heparin-binding angiogenic growth factor involved in various physiopathological processes, including tumor neovascularization. Accordingly, FGF2 is considered a target for antiangiogenic therapies. Thus, numerous natural/synthetic compounds have been tested for their capacity to bind and sequester FGF2 in the extracellular environment preventing its interaction with cellular receptors. We have exploited surface plasmon resonance (SPR) technique in search for antiangiogenic FGF2 binders/antagonists. In this review we will summarize our experience in SPR-based angiogenesis research, with the aim to validate SPR as a first line screening for the identification of antiangiogenic compounds.
. Schematic representation of the neovascularization process. Adapted from [14] .
Surface Plasmon Resonance (SPR) Spectroscopy for the Study of the Angiogenesis Process
A typical setup of a solid-phase bioassay based on SPR spectroscopy is shown in Figure 2 .
Polarized beam of monochromatic visible light is passed through a prism fitted with a glass slide coated with about 50 nm of gold (or other metal). The light is reflected off the gold and its intensity is detected at the specular angle. An electric field intensity, known as an evanescent wave, is generated when the light strikes the glass. This evanescent wave interacts with, and is absorbed by, free electron clouds in the gold layer, generating electron charge density waves called plasmons and causing a reduction in the intensity of the reflected light. The angle corresponding to the sharp intensity minimum that occurs at the SPR condition is called resonance angle. It depends on the refractive index (RI) of the material above and near (below 300 nm) the gold surface, as it is sampled by the evanescent light intensity. The resonance angle can be monitored by following the specularly reflected light intensity versus angle at fixed wavelengths or versus wavelength at fixed angle. In a SPR assay, the receptor specific for a particular analyte is chemically immobilized onto the gold film. When the sensor is exposed to a sample containing that analyte, the binding of the analyte to the receptor causes a change of the RI at the metal surface resulting in the shift of the resonance angle and providing labelfree transduction of the binding reaction. Due to its peculiar architecture, SPR bioassays add to labelfree molecular recognition several advantages, including the ability to investigate and manipulate minute concentrations of molecules semi-automatically, in real time and multiplexed way and the access to information spanning from straight ON-OFF sensing to binding thermodynamics and kinetics. For these reasons SPR represents a powerful asset in the study of biomolecular interactions, including the molecular bases of angiogenesis [15] [16] [17] [18] [19] [20] [21] [22] [23] . As mentioned above, AGFs establish a network of extracellular interactions in order to exert their full angiogenic potential. Indeed, a complex molecular "interactome" due to the cross-talk among cell surface receptors, ECM components, and free molecules appears to modulate the angiogenic balance in normal and pathological settings [7] . In this context, SPR has been usefully exploited to demonstrate and/or characterize the binding of AGFs with their interactors, including cell surface signalling receptors (Table 1 ) and extracellular proteoglycans ( Table 2) .
From the analysis of these tables it emerges that the binding parameters may vary significantly not only among different binding partners but also for the same interactors in different studies. These discrepancies may be due to suboptimal data and/or over-interpreted results [15] [16] [17] [18] [19] [20] [21] [22] [23] ; different immobilization procedures of the ligand; the use of different molecular forms of the ligand and/or of the analyte (e.g., different receptor isoforms, different AGF variants, glycosaminoglycans (GAGs) of different chemical structure). See also Section 5 for a further discussion about this point.
Beside the characterization of the direct AGF/receptor interaction, SPR has been also employed to measure the concentration of AGFs in body fluids. This has been successfully achieved for HGF [55] [56] [57] and has been proposed also for FGF2 [58] .
Finally, different SPR-based experimental models have been set up and used for the identification of antiangiogenic compounds (Table 3) . With these models, various promising inhibitors (including neutralizing antibodies directed against AGFs or their receptors) have been identified and characterized for their molecular mechanism(s) of action (see references in Table 3 ). Table 1 . SPR analysis of the interaction of AGFs with their signalling receptors. SPR was used to assess the kinetics of interaction between the free AGF (analyte) and the extracellular domain of the cognate signalling receptor immobilized to the sensor chip (ligand).
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Immobilized receptor Binding parameters Reference FGFR1 is expressed by ECs in vivo [101] . In vitro, ECs of different origin express FGFR1 [102] and, under some circumstances, FGFR2 [103] , whereas the expression of FGFR3 or FGFR4 has never been reported in endothelium. The interactions of FGFs with FGFRs occur with high affinity [dissociation constant (K d ) = 10-550 pM] and trigger the activation of complex signal transduction pathways [104] . However it must be pointed out that, to induce a full angiogenic response, FGF2
needs also to interact with integrin  v  3 [105] , ganglioside GM1 [106] and HSPGs (discussed below). [107] . HSPGs can link to the plasma membrane through a hydrophobic transmembrane domain of their core protein or through a glycosyl-phosphatidylinositol (GPI) anchor covalently bound to the core protein. Typical transmembrane HSPGs are syndecans, the most represented transmembrane HSPGs in ECs [108] . Glypicans and cerebroglycan are typical GPIanchored HSPGs. Perlecan is instead a typical peripheral membrane HSPG [109] .
HSPGs present at the basal site of blood vessels act as receptors for basement membrane proteins.
HSPGs present at the luminal surface of ECs [110] contribute to the anticoagulative properties of the vessel surface by binding proteases of the intrinsic coagulation cascade [111] and act as receptors or co-receptors for a variety of cytokines and growth factors, including FGF2. Usually the binding of these proteins to HSPGs occurs via their GAG-chains (discussed below).
HSPGs exist also in free form following their mobilization from cell-surface or ECMs by proteolytic digestion of their core protein (for transmembrane HSPGs) or by the action of phospholipase (for GPI-anchored HSPGs). Also, free GAGs can be generated by enzymatic digestion of HSPGs GAG-chain (reviewed in [112] ). The biological consequences of HSPGs/FGF2 interaction are manifold: FGF2 binding to EC-surface HSPG promotes angiogenesis in vitro and in vivo [113] by direct activation of intracellular signalling [113] , by mediating FGF2 internalization [114] , and/or by presenting FGF2 to FGFRs in a proper conformation [112] . Also, ECM-associated HSPGs act as a reservoir for FGF2 that is protected from degradation [115] and accumulates in the microenvironment to sustain a long-term stimulation of ECs [116] (Figure 3 ). GAGs are negatively charged polysaccharides composed of repeating disaccharide units whose prototype is heparin. Heparin is a natural polysaccharide produced by mast cells. Once released, it regulates coagulation through the binding to coagulation factors such as antithrombin III and heparin cofactor II [117] . Also, like HSPGs, heparin binds to a variety of enzymes, cytokines and growth factors, including FGF2 [118] . This capacity, that depends on distinct chemical properties of the polysaccharide chains, can be exploited to design heparin-like drugs for pharmacological interventions in a variety of pathologic conditions including thrombosis, neoplasia and viral infection [94] .
The interaction of heparin/HSPGs with FGF2 occurs with a K d equal to 2-200 nM. Both heparin and GAGs/HSPGs from ECs bind FGF2 and protect it from inactivation and proteolytic degradation [119, 120] . Also, free GAGs favour the delivery of FGF2 to the blood supply to stimulate angiogenesis by increasing the radius of diffusion of the growth factor [121] . Depending on its concentration, free heparin can act as a FGF2 agonist, inducing oligomerization of FGF2 [122] that is required for its full biological response [123] , or as a FGF2 antagonist, sequestering FGF2 in the extracellular environment, hampering its interaction with ECs and inhibiting its biological activity [115] .
Heparin and HSPGs can interact also with FGFRs. Indeed, heparin/HSPGs, FGF2 and FGFR1 form a ternary complex in which the GAG chain interacts with both FGF2 and FGFR [124] . In this model, FGF2 mediates the interaction of HSPG-deficient CHO cells overexpressing FGFR1
to a monolayer of CHO cells expressing HSPGs but not FGFRs [128] . As a consequence of its capacity to interact with any of the three molecular partners involved in the interaction, the putative inhibitor is anticipated to prevent the formation of the HSPG/FGF2/FGFR1 ternary complex resulting from the simultaneous binding of FGF2 to HSPGs and FGFR1 expressed on neighbouring cells. However, the available in vitro and in vivo experimental models for testing these compounds may be quite complex, time-consuming and expensive, calling for additional models overcoming these drawbacks. SPR assays may fit these requirements, being handy-user, reliable, and high-throughput.
Extracellular FGF2 Antagonists

Anti-FGF2 Peptides
Several ECM components, their degradation products or related synthetic peptides affect FGFdriven angiogenesis. Thrombospondins (TSP) are modular glycoprotein secreted by ECs that bind to
HSPGs and integrin receptors [131] . TSP-1 exerts an antiangiogenic effect that is due, at least in part, to its capacity to bind FGF2 [132] , preventing its interaction with HSPGs and FGFRs and inhibiting its mitogenic and chemotactic activity on ECs. TSP-1 also prevents FGF2 accumulation in the ECM and favors matrix-bound FGF2 mobilization, generating inactive TSP-1/FGF2 complexes [133] . Fibstatin is a fibronectin fragment that binds FGF2 and inhibits FGF2-dependent proliferation, migration and tubulogenesis of ECs in vitro and angiogenesis and tumor growth in vivo [134] .
A variety of serum components can bind and regulate FGF2.  2 -Macroglobulin ( 2 M) is a plasma protein that acts as a protease inhibitor and binds a variety of cytokines and growth factors [135] .  2 M sequesters FGF2 in the extracellular environment inhibiting its cell interaction, protease-inducing activity [136] , and mitogenic capacity [135] . Pentraxin 3 (PTX3) is a soluble pattern recognition receptor with unique functions in various physio-pathological conditions released by mononuclear phagocytes and ECs [137] . Its functions relay on its capacity to bind different molecules, including FGF2 [138] . PTX3 prevents the binding of FGF2 to EC surface FGFRs, inhibits EC proliferation and migration, and FGF2-dependent neovascularization and tumorigenesis in vivo [138] . PDGF-BB [139] , PF4 [140] , CXCL13 [141] bind FGF2, inhibiting its interaction with HSPGs and FGFR1, FGF2 internalization, mitogenic and/or anti-apoptotic activity of cultured ECs and angiogenesis in vivo.
Several peptides derived from FGF2, FGFRs or the natural FGF2-binders described above have been demonstrated to exert an inhibitory activity on the FGF2/FGFR system (Table 4) . Among the more than 80 FGF2 antagonist peptides so far described, only a few of them have been identify or characterized by SPR analysis. Nevertheless, these studies show the potentiality of this technology for a systematic identification of FGF2 inhibitors. Regarding peptides that bind and sequester FGF2, SPR has been exploited to demonstrate that the FGF2-derived peptide KRTGQYKLC inhibits FGF2/FGFR1 interaction by binding to FGF2 itself rather than to FGFR [74] .
Regarding peptides that bind and mask FGF2 receptors, a 16-mer oligopeptide with no sequence homology to FGF2 but endowed with conformational similarity to its putative receptor-binding domain was demonstrated to effectively bind to FGFR1 immobilized to a SPR sensorchip [82] . Also, the high-through-put feature of SPR allowed a systematic study of the binding of up to 10 FGF-derived peptides (named dekafins) to the D2-D3 domain of both FGFR1-IIIc and FGFR2-IIIb [28] . Also, SPR
has been used to demonstrate that endostatin binds to HSPGs, suggesting its angiostatic activity may depend, at least in part, on its capacity to mask these receptor to FGF2 [81] . Finally, SPR has been used to analyze large panels of TSP-derived [59] or PTX3-derived peptides [92] . In our previous work, by assaying a large panel of synthetic peptides encompassing the N-terminal extension of human PTX3 we were able to identify the FGF2-binding domain of PTX3 in the amino acid sequence 97-110 [92, 138] . More recently, a series of synthetic peptides based on amino acid sequence PTX3 (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) and containing different mutations in the Ala-Arg-Pro-Cys-Ala (ARPCA) motif ( Figure 5A) were assessed for their FGF2-binding and antiangiogenic activity in vitro and in vivo [169] . As a preliminary experiment, the peptides were tested for their capacity to prevent the binding of FGF2 to FGFR1-IIIc (D1-D3) immobilized to a SPR sensorchip. Interestingly, a significant correlation was found between the capacity of these peptides to inhibit FGF2/FGFR1-IIIc interaction in the SPR-based assay and their ability to prevent the formation of a productive HSPG/FGF2/FGFR1 ternary complex in the FGF2-dependent cell-cell adhesion assay described above ( Figure 5B ).
Anti-FGF2 Polyanionic Heparin-Like Molecules
Free heparin sequesters FGF2 in the extracellular environment, thus exerting an antiangiogenic effect. However, mainly due to its anticoagulant activity and binding aspecificity, unmodified heparin cannot be used as an antiangiogenic drug [127] . This started a series of researches aimed at identifying non-anticoagulant heparin analogous and polyanionic compounds endowed with a more specific FGF2 antagonist activity (reviewed in [7, 130, 170] ). In this context, our laboratory has been involved in the study of a powerful and versatile class of heparin-like molecules originated by chemical and enzymatic modifications of the polysaccharide K5 (reviewed in [171] ). K5 is produced by E. coli and has the same structure of the biosynthetic precursor of heparin/HS. This allows the chemical synthesis of novel heparin-like K5 derivatives characterized by different patterns of sulfation and chemical structure and endowed with a significant antiangiogenic capacity but devoid of anticoagulant a ctivity [172] .
On this basis, we decided to assess whether SPR screening of K5 derivative/FGF2 binding might provide a valuable hint for structure-function correlation studies and might have a predictive value for the antiangiogenic potential of the heparin-like compound under test. To this purpose, in a first set of experiments we immobilized FGF2 to a SPR sensorchip and we used this assay to evaluate the individual binding capacity to FGF2 of a large panel of K5 derivatives differing for sulfation degree and chemical structure. Binding to FGF2 occurs through the negatively charged sulfated groups of the GAG [112] . Accordingly, we found a significant correlation between the degree of sulfation of K5 derivatives [expressed as sulfate/carboxyl group (S/C) ratio] and their capacity to bind FGF2 immobilized to the sensorchip [measured as the amount of K5 derivative that binds surfaceimmobilized FGF2 at the equilibrium] ( Figure 6 ).
It is worth noticing that we intentionally avoided using in this analysis the binding affinities evaluated from the SPR data. The reason is that the state-of-the-art physicochemical models available for their evaluation rely on the approximations of bimolecular interactions described by the Scatchard's equation [173, 174] that are definitively too tight for the molecular system under evaluation. Indeed, the specific binding to FGF2 dependents not only on the overall sulfation degree of GAGs but also on the presence and number of definite sequences of sulfated groups within their backbone structure and may involve mechanisms of cooperative interaction [175] . This point reflects a pivotal basic aspect of the discussion about reliability and accuracy of binding parameters evaluated by SPR (and by solidphase bioassays in general) and about their actual or presumed difference with the parameters evaluated in free solution and in cell-based assays (see below for a further discussion about this crucial point).
In a second set of experiments, the K5 derivatives were assayed for their capacity to prevent the formation of a productive HSPG/FGF2/FGFR1 ternary complex in the FGF2-dependent cell-cell adhesion assay described above. Although with low statistical significance, a correlation trend appears to exist between the capacity of K5 derivatives to inhibit FGF2-dependent HSPG/FGF2/FGFR1 ternary complex formation and their ability to bind immobilized FGF2 (Figure 7) . Figure 6 . SPR runs of FGF2/K5 derivative interaction. FGF2 was immobilized to a sensorchip as described in [133] . Immobilized BSA was used as control and for blank subtraction. The various K5 derivatives (30 nM) were injected onto the FGF2-or BSAcoated sensor chips for four minutes and washed until full dissociation. After each run, the sensor chips were regenerated by a 2 M NaCl pulse [133] . These data support the hypothesis that SPR-generated parameters obtained from the analysis of the direct interaction of FGF2 with heparin-like polyanionic compounds may provide useful hints about the structure/function relationship of FGF2 antagonists. However, as shown in Figure 7 , it is apparent that some K5 derivatives endowed with a very similar FGF2-binding capacity may show a quite different ability to prevent HSPG/FGF2/FGFR1 ternary complex formation and vice versa. This may be due to the capacity of some K5 derivatives to interfere directly with FGF2/FGFR1 interaction rather than with FGF2/HSPG interaction, calling for additional SPR experiments with sensorchipimmobilized FGFR1 (see Figure 5 ).
As described above, FGF2 binds to HSPGs anchored to the surface of ECs. In order to more closely mimic the biological environment in which FGF2 antagonists may act, we exploited a second SPR experimental model in which heparin was immobilized to a SPR sensorchip and FGF2 was used as an analyte were performed [94] . FGF2 binds to immobilized heparin in a specific ( Figure 8A On this basis, a series of low molecular weight (LMW) K5 derivatives were evaluated for their capacity to prevent the binding of FGF2 to immobilized heparin and the SPR-generated data were compared to the data obtained when the same compounds were tested for the capacity to inhibit the formation of the HSPG/FGF2/FGFR1 ternary complex in the cell-cell adhesion assay described above.
A clear correlation, exists between the results provided by the two assays ( Figure 8C ). This is in fair agreement with the results shown in Figure 7 , further supporting the possibility to use SPR-based assays for the screening of polyanionic heparin-like FGF2 antagonists.
Interestingly, a similar correlation was found also when the SPR-generated data were challenged against the results obtained when the LMW-K5 derivatives were evaluated for their capacity to inhibit FGF2-dependent EC proliferation and sprouting, two widely diffused angiogenesis-related assays (for further details, see [94] ). Finally, those compounds that turned out to be efficient FGF2 antagonists in the SPR assay showed a significant capacity to inhibit FGF2-angiogenesis in vivo in the chick embryo chorionallantoic membrane model [94] . These observations strongly support the exploitation of SPR measurements as a first-lane screening predictive of antiangiogenic activity.
The identification of lead compound(s) from a large library is only the first step in the development of effective antiangiogenic drugs. Indeed, lead compounds must be properly modified to increase their efficiency, specificity and safety. Also, this phase of the research calls for affordable and reliable systems that allow the real-time monitoring of the structure-function modifications.
Understanding the Surface-Confined Molecular Recognition: towards an Integrated Biosensing Strategy
As introduced in Section 2, SPR has been exploited to demonstrate and/or characterize the binding of AGFs with their interactors. However, as it emerges from Table 1 and 2, evaluation of kinetic and thermodynamic parameters by SPR experiments and data from different laboratories often provide significantly different results. According to the revised literature this may origin from various "biosensing" as well as "molecular" reasons, including: i) suboptimal data and/or over-interpreted results. A long list of these flaws, that are outside the target of this review, has been reported in details in the survey of commercial optical biosensor literature series [15] [16] [17] [18] [19] [20] [21] [22] [23] . It is important to note that a broad and detailed array of "guidelines" for the interpretation of SPR results is reported in these reviews. If correctly applied, these guidelines would reduce by a great extent the misinterpretations of SPR data, with great benefits for SPR studies in general and angiogenesis in particular.
ii) "lead up" or "lead down" experiments (e.g., the alternative choice to immobilize the AGF or its receptor onto the sensorchip surface). According to the state-of-the-art theory, the alternative choice of immobilization should lead to the same binding parameters. However, many "immobilization-driven" SPR spectroscopy ultimately relies on measuring the variation of the RI at the solid-solution interface that hosts the recognition event. However, any species adsorbed at the interface within few hundreds of nanometers can sort a variation of the RI and in turn generate a detection signal.
Therefore, interpretation of SPR data might result problematic under not well-controlled conditions, as it is the case for non-specific adsorption, ligand-induced conformational changes, or multimeric and allosteric interactions. Also, SPR might present difficulties when utilized with low molecular weight analytes, since binding might not sort a measurable RI change. To overcome these problems, SPR experiments might be complemented by replicate experiments performed with label-free biosensors that feature alternative transduction mechanisms, such as quartz crystal microbalances that feature mass-based transduction, nanomechanical microcantilevers that feature mass-or energy-based transduction, electrochemical impedance spectroscopy, or isothermal titration (nano)calorimetry. All of these alternative techniques present advantages as well as drawbacks with respect to SPR.
Integration of different biosensors [176] will be more effective when an adequate understanding and control of ligand-receptor interactions confined at solid-solution interfaces and of the confining environment (including immobilization of the biomolecules onto the solid-phase) will be achieved On this subject, research is at the beginning and the literature somehow contradictory, pointing to substantial [176] or negligible [17, 19] thermodynamic difference between the two systems. Basically, "surface effects" are recognized and qualitative caveat and solutions have been proposed. A throughout, updated, guideline for good practices can be found in the above cited reviews about commercial optical biosensor literature [15] [16] [17] [18] [19] [20] [21] [22] [23] , in ref. [177] and, generally, in the application-notes supplied by the instrument dealers.
An alternative, promising evolution path is marked down by the development of a thermodynamic framework able to accurately describe ligand-receptor interactions confined at solid-solution interfaces [178, 179] .
Conclusions
Angiogenesis is the process of generating new capillary blood vessels. Uncontrolled neovascularization is observed in tumor growth and in angioproliferative diseases [2] . Tumors cannot grow larger than a few square millimetres as a mass unless a new blood supply is induced [1] . Hence the control of the neovascularization process may affect tumor growth and represent a novel approach to angiogenesis-dependent disease therapy, including neoplasia [180] . A complex molecular "interactome" due to the cross-talk among cell surface receptors, ECM components, and free AGFs appears to modulate the angiogenic balance in normal and pathological settings [7] . In this context, SPR can be usefully exploited to demonstrate and/or characterize the interaction of AGFs with their interactors and for the screening and characterization of antiangiogenic compounds.
SPR is a widely used powerful technology to study macromolecular interaction. Originally released in 1991, it has been used and cited in up to 10,000 papers in the last 12 years. Nevertheless, SPR has been sparingly employed in the study of angiogenesis-related molecules. In effect, a PubMed search on SPR and angiogenesis yielded only 80 papers (published from 1993 to date), 50% of them being devoted to the study of the molecular bases of the interaction of angiogenic growth factors with their receptors and the remaining ones to the exploitation of SPR for the identification of antiangiogenic compounds. Thus, the full potential of SPR in the study of angiogenesis remains largely unexploited.
Here, using the FGF2/FGFR1 system as a prototypic angiogenesis-related target, we have evidenced how SPR-based assays can be successfully used in the search and development of antiangiogenic compounds belonging to different classes of compounds, like synthetic peptides and heparin-like molecules.
It must be pointed out that human tumors in advanced stages of growth, usually characterized by a high degree of vascularization, may express various AGFs, suggesting that tumor neovascularization may represent the result of the simultaneous action of different AGFs [181] . Therefore, "multivalent" compounds (able to bind different AGFs) may be highly effective in inhibiting angiogenesis and tumor progression in vivo. Relevant to this point, several AGFs are endowed with heparin-binding capacity and must interact with HSPGs receptors to exert their full angiogenic potential [7] . To this respect, SPR-based assays may be of great advantage. Large libraries of putative HSPGs-antagonist can be easily and rapidly screened against a panel of heparin-binding AGFs in search of possible multitarget compounds able to inhibit simultaneously the interaction of different AGFs with heparin/HSPGs immobilized to the sensorchip (Table 5 ). 
